KBC Group NV Has $63.12 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

KBC Group NV cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 39.4% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 193,550 shares of the biopharmaceutical company’s stock after selling 125,762 shares during the period. KBC Group NV’s holdings in Alnylam Pharmaceuticals were worth $63,115,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Atlantic Union Bankshares Corp bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $30,000. SVB Wealth LLC acquired a new position in Alnylam Pharmaceuticals in the first quarter valued at $27,000. Ameritas Advisory Services LLC acquired a new position in Alnylam Pharmaceuticals in the second quarter valued at $42,000. AlphaQuest LLC bought a new stake in Alnylam Pharmaceuticals during the second quarter valued at $43,000. Finally, Parkside Financial Bank & Trust lifted its stake in shares of Alnylam Pharmaceuticals by 32.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 179 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 44 shares during the period. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.2%

ALNY opened at $452.74 on Thursday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The firm has a market capitalization of $59.81 billion, a PE ratio of -183.30 and a beta of 0.30. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The company’s 50-day moving average is $458.85 and its 200 day moving average is $381.24.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $1.51. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm had revenue of $1.25 billion during the quarter, compared to analyst estimates of $943.37 million. During the same period in the previous year, the company posted ($0.50) EPS. The company’s revenue for the quarter was up 149.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ALNY. Needham & Company LLC lifted their target price on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a report on Thursday, July 31st. Piper Sandler reaffirmed an “overweight” rating and set a $489.00 price objective (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 8th. Truist Financial increased their target price on shares of Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Finally, Stifel Nicolaus lifted their price target on shares of Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the company a “buy” rating in a research note on Monday, October 6th. Twenty-three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $482.17.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,405 shares of the stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $635,130.25. Following the completion of the sale, the executive vice president owned 27,438 shares in the company, valued at approximately $12,403,347.90. This trade represents a 4.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 8,924 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the transaction, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,568,138.45. This represents a 12.01% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 66,696 shares of company stock valued at $30,430,694 over the last 90 days. 1.20% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.